← Back to patent-cliff list
AD-04(ADvantage Therapeutics)
Tier C — Watch / tradeAD-04(ADvantage Therapeutics)
ADvantage Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：Alhydrogel
Indications (approved)：Alzheimer's disease
Regional status
US
-
EU
Phase II
2023-11-08
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AD-04(ADvantage Therapeutics)?
Approved indications include: Alzheimer's disease.
When does the AD-04(ADvantage Therapeutics) patent expire?
No public expiry year is available for AD-04(ADvantage Therapeutics) yet; this page updates once verified.
How do I get a quote for AD-04(ADvantage Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02